HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
An experienced healthcare executive and expert in HTL’s therapeutic areas, in particular dermatology and medical aesthetics, François Fournier brings more than 20 years’ experience in corporate strategy, business execution, and international leadership.
Prior to joining HTL, François Fournier, of French and American nationality, worked in many
countries and several continents in different management positions at pharmaceutical companies,
including most recently at Virbac (as president and CEO of Virbac North America based in Dallas) and previously at Smith & Nephew and Galderma.
Read more below
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.